Korean medical AI firm Coreline Soft has secured two major international partnerships that significantly expand its global footprint in lung disease diagnostics. France’s national cancer institute selected the company as the exclusive supplier for a national lung cancer screening program, and Boehringer Ingelheim Taiwan adopted its AI software to support clinical trials in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD).

On Monday, Coreline Soft said it was chosen as the sole AI software supplier for France's nationwide lung cancer screening initiative led by the French National Cancer Institute (INCa).

This marks France’s first government-led lung cancer screening program and will enroll up to 20,000 participants across the country over the next four to five years.

The program is co-managed by Assistance Publique–Hôpitaux de Paris (AP-HP), France’s largest public hospital group, and the Civils Hospices of Lyon.

Following rigorous performance evaluation, Coreline Soft's AI solution was selected as the only candidate.

The company said the agreement will proceed through UGAP, France’s centralized public procurement agency, where Coreline Soft is the only lung cancer screening software vendor currently registered.

The solution being deployed, AVIEW LCS Plus, is a core product within Coreline Soft’s CORE:XAI platform. It enables simultaneous detection of three major thoracic disease indicators --pulmonary nodules, emphysema, and coronary artery calcification -- using a single low-dose chest CT scan.

“This contract with the French government, following our previous success with the U.K. National Health Service’s EDIN project, is a major validation of our AI technology and global scalability,” Coreline Soft CEO Kim Jin-kook said. “Winning government-backed screening programs provides a strong entry barrier for competitors and ensures long-term partnerships, especially in Europe and the U.S., where we aim to accelerate further expansion.”

In a separate development disclosed Tuesday, Coreline Soft said it will supply its AVIEW Lung Texture software to Boehringer Ingelheim Taiwan.

Boehringer Ingelheim plans to deploy the AI tool across major tertiary hospitals in Taiwan to gather real-world data on its approved antifibrotic drug Ofev (ingredient: nintedanib) and to support patient selection and monitoring for clinical trials involving BI 1015550 (branded nealandamilast), an investigational therapy targeting ILD and ILA (interstitial lung abnormalities).

AVIEW Lung Texture analyzes chest CT images within minutes, quantifies fibrotic patterns, and classifies them by severity.

It integrates seamlessly with hospital systems such as PACS and RIS, and delivers results via a web-based viewer that allows clinicians and researchers to access and share data in real-time. This capability is expected to significantly improve patient screening speed and enable quantifiable tracking of treatment response.

“Boehringer Ingelheim’s decision to directly purchase and distribute our AI software to hospitals is a testament to the clinical credibility of our technology,” CEO Kim said. “We intend to build a research ecosystem that supports early diagnosis and accelerated access to next-generation therapies for ILD patients.”